- Home
- TAC vs DYN Comparison
TAC vs DYN Comparison
Compare TAC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | DYN |
|---|---|---|
| Founded | 1909 | 1984 |
| Country | Canada | United States |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TAC | DYN |
|---|---|---|
| Price | $12.94 | $17.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $23.67 | ★ $37.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.82 | $7.01 |
| 52 Week High | $17.88 | $25.00 |
Technical Indicators
Market Signals| Indicator | TAC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 48.22 |
| Support Level | $12.08 | $16.34 |
| Resistance Level | $13.94 | $20.08 |
| Average True Range (ATR) | 0.45 | 1.17 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 76.04 | 4.41 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.